Literature DB >> 3315370

Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control.

D Daneman1, C Clarson.   

Abstract

We studied residual beta-cell function in 84 children with IDDM to assess (1) relationship between basal and stimulated C-peptide concentrations; (2) reproducibility of testing (Group 1, n = 20); (3) the effect of exogenous insulin on test interpretation (Group II, n = 20); and (4) impact on metabolic control. Sustacal (a mixed liquid meal) was utilized as the test stimulus. In C-peptide positive subjects (n = 44) there was a strong correlation between basal and peak C-peptide concentrations (r = 0.88, p less than 0.001). In Group 1 subjects, Sustacal proved to be a highly reproducible test stimulus producing identical results on two tests 7-14 days apart. The results of the tests were not affected by the administration of subcutaneous regular insulin prior to the second test in Group II. Peak C-peptide correlated inversely with HbA1, insulin dose, and disease duration (r = -0.29, -0.40, and -0.33 respectively, p less than 0.05) and positively with age (r = 0.34, p less than 0.05). We conclude that Sustacal is a highly reproducible stimulus to residual beta-cell function in IDDM and is not affected by exogenous insulin. This residual insulin secretion has a small but significant effect on glycemic control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315370

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  8 in total

Review 1.  The rise and fall of insulin secretion in type 1 diabetes mellitus.

Authors:  E B Tsai; N A Sherry; J P Palmer; K C Herold
Journal:  Diabetologia       Date:  2006-01-11       Impact factor: 10.122

2.  Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Authors:  K C Herold; S E Gitelman; S M Willi; P A Gottlieb; F Waldron-Lynch; L Devine; J Sherr; S M Rosenthal; S Adi; M Y Jalaludin; A W Michels; J Dziura; J A Bluestone
Journal:  Diabetologia       Date:  2012-10-21       Impact factor: 10.122

3.  Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus.

Authors:  Soumya Adhikari; Beverley Adams-Huet; Yu-Chi A Wang; James F Marks; Perrin C White
Journal:  Pediatrics       Date:  2009-03-02       Impact factor: 7.124

Review 4.  Treatment of type 1 diabetes with anti-CD3 monoclonal antibody.

Authors:  Mariela Glandt; William Hagopian; Kevan C Herold
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 9.306

5.  Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.

Authors:  Jesper S Sørensen; Jesper Johannesen; Flemming Pociot; Kurt Kristensen; Jane Thomsen; N Thomas Hertel; Per Kjaersgaard; Caroline Brorsson; Niels H Birkebaek
Journal:  Diabetes Care       Date:  2013-08-29       Impact factor: 19.112

6.  Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity.

Authors:  Youhei Fujioka; Tsuyoshi Okura; Keisuke Sumi; Kazuhisa Matsumoto; Kyoko Shoji; Risa Nakamura; Kazuhiko Matsuzawa; Shoichiro Izawa; Masahiko Kato; Shinichi Taniguchi; Kazuhiro Yamamoto
Journal:  J Diabetes Investig       Date:  2017-06-19       Impact factor: 4.232

Review 7.  New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Authors:  S Cernea; P Pozzilli
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

8.  Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.

Authors:  Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson
Journal:  Diabetes Care       Date:  2012-10-30       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.